| Anti–interleukin‐6 receptor tocilizumab for severe juvenile idiopathic arthritis–associated uveitis refractory to anti–tumor necrosis factor therapy: a multicenter study of … V Calvo‐Río, M Santos‐Gómez, I Calvo, MI González‐Fernández, ... Arthritis & Rheumatology 69 (3), 668-675, 2017 | 160 | 2017 |
| Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients V Calvo-Río, R Blanco, E Beltrán, J Sánchez-Bursón, M Mesquida, ... Rheumatology 53 (12), 2223-2231, 2014 | 145 | 2014 |
| Epidemiology of uveitis in a Western urban multiethnic population. The challenge of globalization V Llorenç, M Mesquida, M Sainz de la Maza, J Keller, B Molins, ... Acta Ophthalmologica 93 (6), 561-567, 2015 | 140 | 2015 |
| Interleukin-6 blockade in ocular inflammatory diseases M Mesquida, A Leszczynska, V Llorenç, A Adán Clinical & Experimental Immunology 176 (3), 301-309, 2014 | 134 | 2014 |
| The role of inflammation in diabetic eye disease M Mesquida, F Drawnel, S Fauser Seminars in Immunopathology 41, 427-445, 2019 | 130 | 2019 |
| Tocilizumab treatment for refractory uveitis-related cystoid macular edema A Adán, M Mesquida, V Llorenç, G Espinosa, B Molins, MV Hernández, ... Graefe's Archive for Clinical and Experimental Ophthalmology 251, 2627-2632, 2013 | 130 | 2013 |
| Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema M Mesquida, B Molins, V Llorenç, MS de la Maza, A Adán Ophthalmology 121 (12), 2380-2386, 2014 | 120 | 2014 |
| Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients N Vegas-Revenga, V Calvo-Río, M Mesquida, A Adán, MV Hernández, ... American Journal of Ophthalmology 200, 85-94, 2019 | 119 | 2019 |
| Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis C Tappeiner, M Mesquida, A Adán, J Anton, AV Ramanan, E Carreno, ... The Journal of rheumatology 43 (12), 2183-2188, 2016 | 119 | 2016 |
| Adalimumab for the treatment of Behçet’s disease: experience in 19 patients D Perra, MA Alba, JL Callejas, M Mesquida, R Ríos-Fernández, A Adan, ... Rheumatology 51 (10), 1825-1831, 2012 | 118 | 2012 |
| Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients A Adán, L Pelegrín, A Rey, V Llorenç, M Mesquida, B Molins, J Ríos, ... Retina 33 (7), 1435-1440, 2013 | 105 | 2013 |
| Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients L Riancho-Zarrabeitia, V Calvo-Río, R Blanco, M Mesquida, AM Adan, ... Seminars in arthritis and rheumatism 45 (3), 361-368, 2015 | 97 | 2015 |
| Behçet disease-associated uveitis successfully treated with golimumab M Mesquida, M Victoria Hernández, V Llorenç, L Pelegrín, G Espinosa, ... Ocular immunology and inflammation 21 (2), 160-162, 2013 | 96 | 2013 |
| Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet's disease: national multicenter study of 177 cases B Atienza‐Mateo, JL Martín‐Varillas, V Calvo‐Río, R Demetrio‐Pablo, ... Arthritis & Rheumatology 71 (12), 2081-2089, 2019 | 93 | 2019 |
| Use of ultra-wide-field retinal imaging in the management of active Behçet retinal vasculitis M Mesquida, V Llorenç, JR Fontenla, MJ Navarro, A Adán Retina 34 (10), 2121-2127, 2014 | 88 | 2014 |
| Twenty-four month follow-up of tocilizumab therapy for refractory uveitis-related macular edema M Mesquida, B Molins, V Llorenç, MV Hernández, G Espinosa, ... Retina 38 (7), 1361-1370, 2018 | 85 | 2018 |
| Certolizumab pegol, a new anti-TNF-α in the armamentarium against ocular inflammation V Llorenç, M Mesquida, M Sainz de la Maza, R Blanco, V Calvo, O Maíz, ... Ocular immunology and inflammation 24 (2), 167-172, 2016 | 80 | 2016 |
| Golimumab as rescue therapy for refractory immune‐mediated uveitis: A three‐center experience M Cordero-Coma, V Calvo-Río, A Adán, R Blanco, C Álvarez-Castro, ... Mediators of Inflammation 2014 (1), 717598, 2014 | 80 | 2014 |
| Successful optimization of adalimumab therapy in refractory uveitis due to Behçet's disease JL Martín-Varillas, V Calvo-Río, E Beltrán, J Sánchez-Bursón, ... Ophthalmology 125 (9), 1444-1451, 2018 | 79 | 2018 |
| The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet’s disease: results of a multicentre open-label study M Santos-Gómez, V Calvo-Río, R Blanco, E Beltrán, M Mesquida, A Adán, ... Clin Exp Rheumatol 34 (6 Suppl 102), S34-S40, 2016 | 77 | 2016 |
